Steba biotech: innovative therapeutic solutions for the treatment of cancers
Steba biotech is a private biotechnology company that is dedicated to the development of solutions to fight cancer.
Steba biotech participates in research into localised prostate cancer, oesophagus cancer, urothelial carcinoma, kidney cancer, pancreatic cancer and triple-negative breast cancer in collaboration with the Memorial Sloan-Kettering Cancer Center (USA), the Weizmann Institute (Israel) and the University of Oxford (United Kingdom).
International medical leaders’ support
Innovations in focal therapies – offering therapeutic alternatives in oncology for solid tumours – have been recognised and supported by stakeholders worldwide in urology, radiology and oncology areas at Oxford and Harvard Universities, the Memorial Sloan-Kettering Cancer Center and other medical centres and research institutes.
Read moreOur Research and Development
Steba biotech conducts a research program in different indications, including: prostate cancer at different stages, oesophagus cancer, upper urinary tract cancer, breast cancer and pancreatic cancer.
Steba biotech is studying potential innovations in different solid tumours, such as:
Prostate cancer in few clicks
The prostate
Low-risk prostate cancer treatments
Prostate cancer and quality of life following a radical treatment
New options in prostate cancer
Patients with low-risk prostate cancer expectations
Urologists’ expectations